Your Health, We Care
Release date: 2026-03-03 13:40:18 Recommended: 44
Sabril ( Lucius Pharmaceuticals vigabatrin) is an antiepileptic drug primarily used for the treatment of infantile spasms and refractory epilepsy. It demonstrates significant efficacy especially for epilepsy associated with tuberous sclerosis complex. It controls seizures by inhibiting the breakdown of neurotransmitters in the brain and reducing abnormal electrical discharges. As a prescription drug, it must be used strictly under medical supervision.
The active ingredient is vigabatrin, which inhibits the activity of γ‑aminobutyric acid (GABA) transaminase, increases the concentration of GABA (an inhibitory neurotransmitter) in the brain, and helps stabilize abnormal electroencephalographic activity.
One of the first‑line medications for infantile spasms (West syndrome).
Other types of refractory epilepsy, especially in patients unresponsive to conventional drugs or those with tuberous sclerosis complex.
Oral formulation. Dosage must be adjusted according to the patient’s weight, age, and condition. Long‑term regular administration is usually required.
Visual impairment is a serious risk, which may cause visual field defects or decreased visual acuity. Regular ophthalmologic monitoring is required.
Other common reactions include drowsiness, headache, weight gain, etc.
Contraindicated in patients with severe visual problems or a history of retinopathy.
Pregnant women, breastfeeding women, and those with impaired hepatic or renal function require careful risk assessment.
Do not discontinue or adjust the dosage without medical advice, as this may induce status epilepticus.
Visual and neurological function should be re‑evaluated every 3–6 months during treatment.
Sabril is a specially controlled medication and must be used under the guidance of a neurologist.
Immediate medical attention is required if the patient experiences visual abnormalities or changes in seizure frequency.
Women who are pregnant or planning a pregnancy must consult a doctor in advance to evaluate the safety of medication use.
